Moderna Inc (MRNA) stock saw a decline, ending the day at $42.58 which represents a decrease of $-1.68 or -3.80% from the prior close of $44.26. The stock opened at $43.98 and touched a low of $42.36 ...

CEO Stéphane Bancel said that he plans to address any partisan hurdles with the incoming Trump administration’s vaccine and ...

We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

撰文丨王聪编辑丨王多鱼排版丨水成文众所周知，根据中心法则，DNA转录为mRNA，mRNA再翻译为蛋白质，mRNA的降解速率是每个基因产生的蛋白质的数量的主要决定因素，而这又会影响细胞功能。例如，对于mRNA疫苗，mRNA存在更长时间会产生更多蛋白质， ...

mRNA疫苗凭借其高度灵活和可调的特性，在众多领域内的应用前景正不断拓宽，特别是在癌症免疫治疗方面，已引起越来越多研究者的关注。近日，浙江大学医学院附属第一医院梁廷波教授和黄星研究员等在Science Bulletin发表了题为“mRNA vaccines for gastrointestinal malignancies: cutting-edge advances and future per ...

Within a cell, DNA carries the genetic code for building proteins. To build proteins, the cell makes a copy of DNA, called mRNA.

Advantage Therapeutics is spinning off some of its age-related disease R&D into a new company called Klothea Bio. | Klothea ...

Messenger ribonucleic acid (mRNA)-based therapeutics and the potential of mRNA as a treatment for various conditions has been ...

Mass Eye and Ear研究人员的一项新的临床前研究表明，一种新的基于mrna的疗法可能能够预防视网膜脱离修复或眼睛创伤性损伤后增殖性玻璃体视网膜病变（PVR）引起的失明和疤痕。目前除了手术之外没有其他治疗PVR的方法，而手术本身具有引起或加重PVR的高风险。他们的研究结果发表在《科学转化医学》（Science Translational ...

Sunshine Biopharma (SBFM) has completed mouse model studies providing proof-of-concept for the Company’s K1.1 mRNA product as a novel ...

A preclinical study by Mass Eye and Ear investigators showed that a novel mRNA-based therapy may be able to prevent blindness ...